How should lightheadedness be evaluated and managed in a patient with multiple sclerosis?

Lightheadedness in Multiple Sclerosis: Evaluation and Management

Lightheadedness in MS patients requires distinguishing true vertigo from non-vertiginous dizziness, as this fundamentally changes your diagnostic and therapeutic approach—true vertigo suggests demyelinating lesions affecting vestibular pathways and warrants MRI evaluation, while lightheadedness without vertigo rarely requires neuroimaging and should prompt evaluation for systemic causes.

Initial Clinical Assessment

Critical Distinction: Vertigo vs. Lightheadedness

First, clarify what the patient means by "lightheadedness":

• True vertigo: False sensation of self-motion, spinning, or visual surroundings rotating—this is the hallmark of vestibular pathway involvement in MS 1
• Lightheadedness/presyncope: Sensation of impaired spatial orientation without spinning—typically NOT from MS lesions 1, 2

Key point: Many patients use "dizziness" vaguely. Ask specifically: "Do you feel like you or the room is spinning?" A confident description of spinning indicates inner ear or central vestibular dysfunction 1.

Specific History Elements

Document these details systematically:

• Onset pattern: Spontaneous vs. positional (head movement triggers suggest BPPV, not MS)
• Duration: Seconds (BPPV), minutes to hours (vestibular migraine or MS), days (vestibular neuritis)
• Associated symptoms during episodes:
  • Hearing loss, tinnitus, aural fullness (suggests Ménière's, not typical MS)
  • New neurologic symptoms (diplopia, dysarthria, limb weakness—suggests MS relapse)
  • Loss of consciousness (NEVER MS—evaluate cardiac/syncope causes)
• Timing relative to MS disease activity: New symptom vs. chronic issue
• Current MS medications: Particularly if recently switched therapies 3

Diagnostic Workup Based on Symptom Type

If TRUE VERTIGO (Spinning Sensation)

This suggests central vestibular pathway involvement and requires imaging:

1. Brain MRI with specific protocol 3:

   • T2-FLAIR sequences (detect demyelinating lesions)
   • T2-weighted imaging
   • Diffusion-weighted imaging (DWI)—essential to exclude stroke
   • Gadolinium-enhanced T1 (identifies active inflammatory lesions)

2. Lesion locations in MS-related vertigo 4:

   • Medulla
   • Cerebellar peduncles (inferior, middle, superior)
   • Pontine tegmentum
   • Intrapontine 8th nerve fascicle (less common than previously thought)
   • Midbrain

Clinical pearl: MS causing acute vestibular syndrome is uncommon (4% of acute vertigo cases) but presents with central oculomotor signs 4. Look for:

• Abnormal smooth pursuit
• Gaze-evoked nystagmus
• Normal head impulse test (h-HIT)—this is critical; peripheral vestibular lesions have abnormal h-HIT, central (MS) lesions have normal h-HIT 4

If LIGHTHEADEDNESS WITHOUT VERTIGO

Neuroimaging has extremely low yield (<1% on CT, 4% on MRI) and is NOT recommended 2.

Instead, evaluate for:

1. Orthostatic hypotension: Check lying and standing blood pressures
2. Autonomic dysfunction: Common in MS, can cause persistent lightheadedness even without obvious orthostatic symptoms 2
3. Medication effects: Review all current medications
4. Dehydration/metabolic causes: Basic labs if clinically indicated
5. Cardiac causes: If concerning features present (exertional symptoms, palpitations)

Do NOT order brain imaging for isolated lightheadedness without vertigo or other neurologic deficits 2.

Management Approach

For MS-Related Vertigo (Demyelinating Lesion Confirmed)

Acute treatment 5:

• High-dose intravenous methylprednisolone (typical MS relapse protocol)
• Consider immunosuppressive therapy if severe or refractory

Symptomatic management:

• Vestibular suppressants (meclizine, dimenhydrinate) for SHORT-TERM use only during acute phase
• Vestibular physical therapy: Recent meta-analysis shows significant efficacy (Hedges' g = 1.451) in reducing dizziness-related disability in MS patients 6

For Non-Vertiginous Lightheadedness

1. Address underlying cause (orthostatic hypotension, autonomic dysfunction, medications)
2. Symptomatic measures:
   • Increase fluid and salt intake if orthostatic
   • Compression stockings
   • Medication adjustment if drug-related
3. Vestibular rehabilitation may still help even without true vertigo 6

Special Considerations

High-Risk Scenarios Requiring Enhanced Vigilance

If patient is on or recently switched from natalizumab, fingolimod, alemtuzumab, or dimethyl fumarate 3:

• MRI every 3-4 months to screen for progressive multifocal leukoencephalopathy (PML)
• Include DWI sequences specifically
• PML can present with ataxia and dizziness

Impact on Quality of Life

Dizziness affects 49-59% of MS patients and significantly impacts quality of life 7:

• Physical and mental health scores decrease as dizziness severity increases
• Higher disability levels correlate with worse dizziness (OR 1.38 for severe vs. mild disability)
• This symptom deserves aggressive management, not dismissal as "just MS"

Common Pitfalls to Avoid

1. Don't assume all dizziness in MS is from demyelination—most lightheadedness is systemic
2. Don't order MRI for non-vertiginous lightheadedness—waste of resources with <1% yield
3. Don't use vestibular suppressants long-term—they delay central compensation
4. Don't forget to check h-HIT—normal test with vertigo suggests central (MS) cause
5. Don't overlook medication side effects, especially in patients on multiple symptomatic treatments 8